442 related articles for article (PubMed ID: 12719883)
1. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial.
Santoso JT; Lucci JA; Coleman RL; Schafer I; Hannigan EV
Cancer Chemother Pharmacol; 2003 Jul; 52(1):13-8. PubMed ID: 12719883
[TBL] [Abstract][Full Text] [Related]
2. Comparison of oral and intravenous hydration and diuretic, choice for protecting cisplatin induced nephrotoxicity.
Dana R; Kachhwaha VS
Indian J Cancer; 1996 Dec; 33(4):168-70. PubMed ID: 9254992
[TBL] [Abstract][Full Text] [Related]
3. High-dose cisplatin therapy using mannitol versus furosemide diuresis: comparative pharmacokinetics and toxicity.
Ostrow S; Egorin MJ; Hahn D; Markus S; Aisner J; Chang P; LeRoy A; Bachur NR; Wiernik PH
Cancer Treat Rep; 1981; 65(1-2):73-8. PubMed ID: 6784924
[TBL] [Abstract][Full Text] [Related]
4. A comparison of the rates of cisplatin (cDDP)--induced nephrotoxicity associated with sodium loading or sodium loading with forced diuresis as a preventative measure.
Leu L; Baribeault D
J Oncol Pharm Pract; 2010 Sep; 16(3):167-71. PubMed ID: 19759050
[TBL] [Abstract][Full Text] [Related]
5. A retrospective evaluation of furosemide and mannitol for prevention of cisplatin-induced nephrotoxicity.
Mach CM; Kha C; Nguyen D; Shumway J; Meaders KM; Ludwig M; Williams-Brown MY; Anderson ML
J Clin Pharm Ther; 2017 Jun; 42(3):286-291. PubMed ID: 28276070
[TBL] [Abstract][Full Text] [Related]
6. Forced euvolemic diuresis with mannitol and furosemide for prevention of contrast-induced nephropathy in patients with CKD undergoing coronary angiography: a randomized controlled trial.
Majumdar SR; Kjellstrand CM; Tymchak WJ; Hervas-Malo M; Taylor DA; Teo KK
Am J Kidney Dis; 2009 Oct; 54(4):602-9. PubMed ID: 19535188
[TBL] [Abstract][Full Text] [Related]
7. Furosemide versus mannitol in Japanese patients with thoracic malignancy who received cisplatin-based chemotherapy using short hydration: study protocol for a randomised controlled trial.
Murakami E; Akamatsu H; Shimokawa T; Wada K; Yamamoto N
BMJ Open; 2019 Dec; 9(12):e029057. PubMed ID: 31831529
[TBL] [Abstract][Full Text] [Related]
8. A randomized trial of saline hydration to prevent contrast nephropathy in chronic renal failure patients.
Dussol B; Morange S; Loundoun A; Auquier P; Berland Y
Nephrol Dial Transplant; 2006 Aug; 21(8):2120-6. PubMed ID: 16611682
[TBL] [Abstract][Full Text] [Related]
9. Mannitol to prevent cisplatin-induced nephrotoxicity in patients with squamous cell cancer of the head and neck (SCCHN) receiving concurrent therapy.
McKibbin T; Cheng LL; Kim S; Steuer CE; Owonikoko TK; Khuri FR; Shin DM; Saba NF
Support Care Cancer; 2016 Apr; 24(4):1789-93. PubMed ID: 26446698
[TBL] [Abstract][Full Text] [Related]
10. Randomized study comparing mannitol with furosemide for the prevention of cisplatin-induced renal toxicity in non-small cell lung cancer: The OLCSG1406 trial.
Makimoto G; Hotta K; Oze I; Ninomiya K; Nakanishi M; Hara N; Kano H; Watanabe H; Hata Y; Nishii K; Nakasuka T; Itano J; Ninomiya T; Kubo T; Ohashi K; Ichihara E; Minami D; Sato A; Tabata M; Maeda Y; Kiura K
Asia Pac J Clin Oncol; 2021 Feb; 17(1):101-108. PubMed ID: 32885583
[TBL] [Abstract][Full Text] [Related]
11. Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin.
Cornelison TL; Reed E
Gynecol Oncol; 1993 Aug; 50(2):147-58. PubMed ID: 8375728
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma: a southwest oncology group study.
Al-Sarraf M; Fletcher W; Oishi N; Pugh R; Hewlett JS; Balducci L; McCracken J; Padilla F
Cancer Treat Rep; 1982 Jan; 66(1):31-5. PubMed ID: 6796269
[TBL] [Abstract][Full Text] [Related]
13. Nephroprotection by theophylline in patients with cisplatin chemotherapy: a randomized, single-blinded, placebo-controlled trial.
Benoehr P; Krueth P; Bokemeyer C; Grenz A; Osswald H; Hartmann JT
J Am Soc Nephrol; 2005 Feb; 16(2):452-8. PubMed ID: 15590762
[TBL] [Abstract][Full Text] [Related]
14. Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents.
Solomon R; Werner C; Mann D; D'Elia J; Silva P
N Engl J Med; 1994 Nov; 331(21):1416-20. PubMed ID: 7969280
[TBL] [Abstract][Full Text] [Related]
15. Perioperative renal protection in patients with obstructive jaundice using drug combinations.
Wahbah AM; el-Hefny MO; Wafa EM; el-Kharbotly W; el-Enin AA; Zaglol A; Atallah MM
Hepatogastroenterology; 2000; 47(36):1691-4. PubMed ID: 11149033
[TBL] [Abstract][Full Text] [Related]
16. [Administration of high doses of cisplatin in 20-minute infusions].
Cirera L; Gay M; Tomé T; Martí M; Huguet J; Plá R
Rev Clin Esp; 1988 Mar; 182(4):192-5. PubMed ID: 3137644
[No Abstract] [Full Text] [Related]
17. Safe, rapid administration of cisplatin in the outpatient clinic.
Brock J; Alberts DS
Cancer Treat Rep; 1986 Dec; 70(12):1409-14. PubMed ID: 3539327
[TBL] [Abstract][Full Text] [Related]
18. Comparison of preventive effects of combined furosemide and mannitol versus single diuretics, furosemide or mannitol, on cisplatin-induced nephrotoxicity.
Takagi A; Miyoshi T; Hayashi T; Koizumi H; Tsumagari K; Yokota C; Nakano T; Matsuo K; Egawa T
Sci Rep; 2024 May; 14(1):10511. PubMed ID: 38714773
[TBL] [Abstract][Full Text] [Related]
19. [The protective effects of two hydration protocols against cisplatin nephrotoxicity].
Guo JH; Song ST; Xu ZL
Zhonghua Zhong Liu Za Zhi; 1994 Jan; 16(1):56-8. PubMed ID: 8033751
[TBL] [Abstract][Full Text] [Related]
20. [Experimental studies on the nephrotoxicity of cisplatin--amelioration of nephrotoxicity by continuous infusion].
Izumi T
Hinyokika Kiyo; 1988 Jan; 34(1):37-45. PubMed ID: 3132030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
